Clinical Trials Browser

Phase 1/2 × Interventional × TAK-659 × Clear all

NCT04079738 2023-09-13

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

Phase 1/2 Terminated

8 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02323113 2023-02-08

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Phase 1/2 Terminated

43 enrolled 27 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute